AI-generated summary
The authors randomized 30 patients with mild-to-moderate dementia to photobiomodulation therapy plus standard treatment or to a sham device plus standard treatment, and assessed cognition, anxiety and depression. They report no difference between the two groups in cognitive scores, depression or anxiety at baseline, after treatment, or one month later. The authors conclude the treatment likely has no significant impact on cognitive status or mood in this group.
- Participants
- 30
- Who or what was studied
- Patients with mild-to-moderate dementia
- Limits stated in the abstract
- The trial was small, with 15 patients per group, and the abstract does not report wavelengths or dosing parameters.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation therapy, Dementia, Depression, Anxiety, Photobiomodulation. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.